Stevanato Group S.p.A. (NYSE:STVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Stevanato Group S.p.A. (NYSE:STVN) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company.

STVN has been the subject of several research reports. CJS Securities initiated coverage on shares of Stevanato Group in a research report on Tuesday, September 19th. They issued an “outperform” rating and a $36.00 price target for the company. Jefferies Financial Group cut shares of Stevanato Group from a “buy” rating to a “hold” rating and decreased their target price for the company from $39.00 to $29.00 in a research report on Wednesday, November 1st. Wells Fargo & Company increased their target price on shares of Stevanato Group from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, July 31st. Stephens initiated coverage on shares of Stevanato Group in a research report on Monday, September 25th. They set an “overweight” rating and a $33.00 target price for the company. Finally, Morgan Stanley decreased their target price on shares of Stevanato Group from $34.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 1st.

Stevanato Group Price Performance

Shares of STVN opened at €27.92 ($30.68) on Tuesday. The company has a 50 day moving average price of €29.62 and a 200-day moving average price of €30.33. Stevanato Group has a fifty-two week low of €14.02 ($15.41) and a fifty-two week high of €36.30 ($39.89). The stock has a market capitalization of $8.25 billion, a PE ratio of 47.32, a PEG ratio of 4.08 and a beta of 0.87. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.91 and a current ratio of 1.41.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings results on Tuesday, October 31st. The company reported €0.16 ($0.18) earnings per share for the quarter, hitting the consensus estimate of €0.16 ($0.18). Stevanato Group had a net margin of 14.05% and a return on equity of 14.87%. The firm had revenue of €295.39 million during the quarter, compared to analysts’ expectations of €305.22 million. Equities analysts predict that Stevanato Group will post 0.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. TimesSquare Capital Management LLC raised its holdings in shares of Stevanato Group by 64.2% in the third quarter. TimesSquare Capital Management LLC now owns 2,032,361 shares of the company’s stock worth $60,402,000 after buying an additional 794,391 shares during the last quarter. Advisors Capital Management LLC raised its holdings in shares of Stevanato Group by 1.3% in the third quarter. Advisors Capital Management LLC now owns 253,617 shares of the company’s stock worth $7,538,000 after buying an additional 3,256 shares during the last quarter. Jag Capital Management LLC purchased a new position in shares of Stevanato Group in the third quarter worth $209,000. GSA Capital Partners LLP purchased a new position in shares of Stevanato Group in the third quarter worth $1,033,000. Finally, Royal Bank of Canada raised its holdings in shares of Stevanato Group by 29.8% in the third quarter. Royal Bank of Canada now owns 252,384 shares of the company’s stock worth $7,501,000 after buying an additional 57,958 shares during the last quarter. Hedge funds and other institutional investors own 10.90% of the company’s stock.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for biopharma and healthcare. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines.